Aclaris Therapeutics Stock Forecast, Price & News

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics or view top-rated stocks.

How has Aclaris Therapeutics' stock price been impacted by Coronavirus?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACRS shares have increased by 919.8% and is now trading at $10.81.
View which stocks have been most impacted by COVID-19.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aclaris Therapeutics.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.82 million. Aclaris Therapeutics had a negative net margin of 1,187.63% and a negative trailing twelve-month return on equity of 54.41%.
View Aclaris Therapeutics' earnings history.

What price target have analysts set for ACRS?

4 Wall Street analysts have issued 1-year target prices for Aclaris Therapeutics' stock. Their forecasts range from $26.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 233.0% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

• Neal S. Walker, President, Chief Executive Officer & Director (LinkedIn Profile)
• Frank Ruffo, Chief Financial Officer & Treasurer (LinkedIn Profile)
• David Gordon, Chief Medical Officer (LinkedIn Profile)
• Joseph B. Monahan, Chief Scientific Officer
• Elaine Morefield, Director-Product Quality

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

Some companies that are related to Aclaris Therapeutics include Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), Arcus Biosciences (RCUS), Mawson Infrastructure Group (WIZP), ChemoCentryx (CCXI), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Schrödinger (SDGR), Indivior (INVVY), Xencor (XNCR), Harmony Biosciences (HRMY), Corcept Therapeutics (CORT), 23andMe (ME), Cryoport (CYRX) and Ligand Pharmaceuticals (LGND).
View all of ACRS's competitors.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $10.81.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $661.90 million and generates $6.48 million in revenue each year. The biotechnology company earns $-51.01 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 59 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at (484) 324-7933, via email at [email protected], or via fax at 484-320-2344.